CareFusion 213, LLC - 722729 - 04/30/2026

Why It Matters

The violations expose patients to unsafe sterile products, risk costly recalls, and threaten BD’s regulatory standing and market reputation.

Key Takeaways

• FDA cited 2,500+ complaints about foreign particles and missing components.
• Investigation failures omitted batch-wide scope, violating 21 CFR 211.192.
• Sterility test failure tied to inadequate biological indicator verification.
• Cleaning logs showed residues despite documented procedures, breaching 21 CFR 211.67.
• BD must overhaul CAPA, lab controls, and contamination programs to avoid recalls.

Pulse Analysis

The FDA’s warning to CareFusion 213 underscores a growing regulatory focus on the integrity of sterile drug manufacturing. Recent industry surveys reveal that nearly one‑third of FDA inspections uncover deficiencies in complaint handling and CAPA effectiveness, driving heightened scrutiny of quality‑system oversight. For a major player like Becton, Dickinson, the cited lapses—ranging from incomplete root‑cause analyses to insufficient laboratory verification of biological indicators—signal systemic gaps that could jeopardize product sterility and trigger enforcement actions, including product seizures or import bans.

Beyond immediate compliance concerns, the letter highlights the financial ripple effects of inadequate contamination control. Cleaning‑validation failures and observed residues suggest that batches may have been released without meeting sterility specifications, raising the likelihood of recalls that can cost tens of millions of dollars and erode customer trust. In a market where hospitals and health systems demand rigorous assurance, any hint of compromised aseptic processing can shift purchasing decisions toward competitors with proven quality‑system robustness.

To mitigate these risks, BD must implement a multi‑layered remediation strategy: revamp investigation protocols to ensure batch‑wide scope, institute quantitative spore‑population verification for all biological indicators, and launch a comprehensive cleaning‑validation program that includes worst‑case residue testing. Strengthening CAPA governance with executive oversight and real‑time trend analytics will also be critical. By aligning its quality infrastructure with the heightened expectations of 21 CFR parts 210 and 211, BD can restore regulator confidence, protect patient safety, and safeguard its market position.